Stoke Therapeutics, Inc. — Director's Dealing 2021

Mar 4, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Stoke Therapeutics, Inc. (STOK)
CIK: 0001623526
Period of Report: 2020-12-28

Reporting Person: Liau Gene (EVP Research & Preclinical Dev)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2020-12-28	Common Stock	M	8000	$0.60	Acquired	21500	Direct
2020-12-28	Common Stock	S	149	$58.73	Disposed	21351	Direct
2021-03-02	Common Stock	M	5195	$0.60	Acquired	26546	Direct
2021-03-02	Common Stock	S	2295	$62.4625	Disposed	24251	Direct
2021-03-02	Common Stock	S	2900	$63.5155	Disposed	21351	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2020-12-28	Employee Stock Option (right to buy)	$0.60	M	8000	Disposed	2028-04-02	Common Stock (8000)	Direct
2021-03-02	Employee Stock Option (right to buy)	$60.00	A	40800	Acquired	2031-03-01	Common Stock (40800)	Direct
2021-03-02	Employee Stock Option (right to buy)	$0.60	M	5195	Disposed	2028-04-02	Common Stock (5195)	Direct

Footnotes

F1: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F2: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $62.00 to $62.93 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F3: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $63.13 to $63.99 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F4: The option vested as to 1/4th of the total shares on January 16, 2018, and then 1/48th of the total shares vest monthly thereafter, subject to the reporting person's continued service to the issuer through each vesting date.

F5: The option vests as to 1/48th of the total shares on April 2, 2021 and then 1/48th of the total shares vest monthly thereafter, subject to the reporting person's continued service to the issuer through each vesting date.